Phase 2 N=5 CNTF Implants for CNGB3 Achromatopsia
Eye Disease · Achromatopsia
Primary: Number of Adverse Events at Six Months Post-Implantation — 10 Adverse Events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=96 Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial
Gastric Cancer
Primary: Response Rate — 28.9; 26.1 percentage of participants
Phase 2 N=36 Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration
Rheumatoid Arthritis
Primary: Bioequivalence Based Upon Dose-Normalized AUC[0-Inf] for MTX — 118.14; 122.63; 116.71 ng*hr/mL/mg
Phase 2 N=41 Linezolid to Treat Extensively-Drug Resistant Tuberculosis
Pulmonary Tuberculosis · Multidrug Resistant Tuberculosis · Extensively Drug Resistant Tuberculosis
Primary: Number of Patients Converted to Sputum Culture Negative in Each Arm, With Data Censored at 4 Months. — 15; 7 participants
Phase 2 N=100 Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability
Phase 2 N=34 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumor
Primary: Clinical Benefit as Defined by the Composite of Complete Response, Partial Response and Stable Disease Lasting 16 Weeks or More Per RECIST 1.1 as a Measure of Disease…
Phase 2 N=34 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Percentage of Participants With Treatment-related, Grade 3+, Non-hematologic Adverse Events Occuring Within 90 Days After Treatment Start — 23.3 percentage of participants
Phase 2 N=7 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children
Dengue Fever
Primary: Number of Solicited Adverse Events Within 21 Days After the First Dose of Dengue Vaccine. — 1; 3; 5; 3 adverse events
Phase 2 N=285 28-day Repeat Dose Study of GSK573719
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Day 29 — 0.013; 0.171; 0.181; 0.163 Liters — p=<0.001
Phase 2 N=100 Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine
Influenza
Primary: Haemagglutination Inhibition (HI) Antibody Titers for the H5N1 Vaccine Strain — 5.0; 5.4; 156.8; 142.1 Titer
Phase 2 N=4 Development of an Ergonomic Wheelchair Pushrim
Spinal Cord Injury
Primary: Change in Functional Status Score
Phase 2 N=51 Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
Non-Hodgkins Lymphoma
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 81 percentage of patients
Phase 2 N=29 Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
Recurrent Adrenocortical Carcinoma · Stage III Adrenocortical Carcinoma · Stage IV Adrenocortical Carcinoma
Primary: The Proportion of Patients Who Achieve a Confirmed Objective Response to Treatment, Either Partial Response (PR) or Complete Response (CR) as Defined by Response…
Phase 2 N=43 Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents
Pertussis · Tetanus · Diphtheria
Primary: Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Following Vaccination With ADACEL® — 100; 100 Percentage of Participants
Phase 2 N=40 Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis
Trichomonas Vaginitis
Primary: Percentage of Participants Cured of Vaginal Trichmonas — 90; 90; 88 percentage of participants